According to Novartis latest financial reports the cash on hand of NOVN is $13.96B, an decrease of -25.00% to 2022. At the end of 2022 company had $18.61B cash on hand. This amount reflects the liquid assets available to the company, which are crucial for its operational flexibility, investment opportunities, and overall financial security.
Year | Cash on Hand | Change |
---|---|---|
2023 | $13.96B | -25.00% |
2022 | $18.61B | -33.79% |
2021 | $28.11B | 148.94% |
2020 | $11.29B | -1.34% |
2019 | $11.45B | -28.30% |
2018 | $15.96B | - |